Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance
Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance
Presently in the current trading session, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is experiencing a notable surge, marking a 22.80% increase to $5.00 as per the latest update. This uptrend in CELZ stock correlates with the regulatory clearance obtained for a novel pharmaceutical product by the company.
目前，在本交易時段中，Creative Medical Technology Holdings, Inc.（納斯達克股票代碼：CELZ）大幅上漲，根據最新消息，上漲22.80％，至5.00美元。CELZ股票的這種上漲趨勢與該公司獲得的新型藥品的監管許可相關。
The U.S. Food and Drug Administration (FDA) has designated CELZ-101, often referred to as ImmCelz, as an orphan drug as publicly disclosed by Creative Medical Technology (CELZ). This innovative therapy aims to shield recipients of pancreatic islet cell transplants against allograft rejection.
正如創新醫療科技（CELZ）公開披露的那樣，美國食品藥品監督管理局（FDA）已將 CELZ-101（通常稱爲 immcelZ）指定爲孤兒藥。這種創新療法旨在保護胰腺胰島細胞移植接受者免受異體移植排斥反應。
For people with fragile Type 1 diabetes, a condition characterized by erratic fluctuations in blood glucose levels, it is a significant breakthrough. CELZ-101, alternatively termed as Supercharged Treg Biologic Immunotherapy (ImmCelz), epitomizes a cutting-edge paradigm in personalized healthcare, leveraging the patient's own regulatory T cells (Tregs) to counter autoimmune and alloimmune responses that may jeopardize insulin-producing cells.
對於脆性 1 型糖尿病（一種以血糖水平不穩定波動爲特徵的疾病）患者來說，這是一項重大突破。CELZ-101，也稱爲增壓Treg生物免疫療法（immcelZ），是個性化醫療保健的尖端典範，它利用患者自身的調節性T細胞（Treg）來對抗可能危及胰島素產生細胞的自身免疫和同種免疫反應。
This groundbreaking therapy is rooted in a proprietary methodology not only amplifying Tregs but also augmenting their efficacy, promising a viable avenue to diminish the necessity for lifelong immunosuppressive measures. The conferment of Orphan Drug Designation by the FDA for CELZ-101 underscores the unwavering dedication of the company towards pioneering therapeutic modalities.
這種開創性的療法植根於一種專有方法，不僅可以放大Treg，還可以增強其療效，這爲減少終身免疫抑制措施的必要性提供了可行的途徑。美國食品藥品管理局授予 CELZ-101 孤兒藥稱號，這凸顯了該公司對開創性治療模式的堅定不移的承諾。
This pivotal achievement catapults the endeavor closer towards offering a sustainable resolution for individuals contending with the persistent challenges of brittle Type 1 diabetes, hallmarked by erratic glycemic fluctuations. It is in consonance with CELZ's overarching mission to enhance the quality of life for patients through the vanguard of regenerative medicine.
這一關鍵成就使我們更接近於爲面臨脆性1型糖尿病持續挑戰的個人提供可持續的解決方案，而脆性1型糖尿病的特點是血糖波動不定。這與CELZ的首要使命一致，即通過再生醫學的先鋒提高患者的生活質量。
The advancement of CELZ-101 marks a significant stride in the domain of cell-based immunotherapy, addressing the imperative requirement for more efficacious interventions in brittle Type 1 diabetes by striving for operational tolerance in islet cell transplantation, potentially liberating patients from the onus of lifelong immunosuppression.
CELZ-101 的進展標誌着基於細胞的免疫療法領域取得了重大進展，通過努力提高胰島細胞移植的手術耐受性，解決了對脆性 1 型糖尿病進行更有效干預的迫切需求，這有可能使患者擺脫終身免疫抑制的責任。
This heralds the debut of the first orphan-designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes. The Orphan Drug Designation accorded by the FDA accentuates the potential of CELZ-101 in fulfilling a substantial unmet need in averting allograft rejection during pancreatic islet cell transplantation, which recently garnered FDA approval.
這預示着第一種針對脆性1型糖尿病的孤兒指定的、基於協同細胞的免疫療法的問世。美國食品和藥物管理局授予的孤兒藥認證突顯了 CELZ-101 在滿足胰腺胰島細胞移植期間避免同種異體移植排斥反應的巨大需求方面的潛力，胰腺胰島細胞移植最近獲得了 FDA 的批准。
This designation confers numerous consequential advantages to bolster the progression of the therapy including tax incentives, exemptions from user fees, and the prospect of market exclusivity post-approval.
這一稱號爲促進療法的進展提供了許多相應的優勢，包括稅收優惠、免除使用費以及批准後市場排他性的前景。
譯文內容由第三人軟體翻譯。